



Despite advancements in medical sciences, significant global challenges still exist in the treatment of simple to complex bacterial infections. Many of these bacteria, such as *Mycobacterium tuberculosis* and *Pseudomonas aeruginosa*, have become drug resistant at an alarming rate. Immunosuppressed patients are significantly at risk, and the resistant infections spread rapidly within both the at-risk and the general populations. The problem is compounded by the lack of release of novel antibiotics due to tougher FDA restrictions.

This discovery using novel antibiotic compounds with a different mode of action is directed toward currently known drug resistant bacterial strains. Pharmaceutical and bio-technology laboratories may benefit through collaboration in optimizing these compounds to increase potency and establish health safety.



(image source: WebMD)

For further information regarding this Technology please contact:

Office of Research Translation

1201 W. University Drive
Edinburg, TX 78539
956-665-3032
ORT@utrgv.edu

A new type of antibiotic compound as Protein Synthesis Inhibitor

Competitive Advantages

- New drug defense against bacterial infections
- Reduction in drug resistant bacteria
- Higher success rate of treatment

Commercial Applications

- Joint drug development facility
- Multi-antibiotic product
- Knowledge sharing

IP Status

- Patent pending
- Licensing available

Status of Development

- Prototyping stage

Lead Inventor



Dr. James Bullard
Associate Professor
James.Bullard@utrgv.edu